Peripartum Mental Health Cohort Study in Guangzhou

September 11, 2023 updated by: Xiu Qiu, Guangzhou Women and Children's Medical Center
The purpose of this study is to determine the incidence,development trajectory and risk factors of the main peripartum mental health problems as well as explore its adverse outcomes.

Study Overview

Status

Recruiting

Conditions

Detailed Description

Peripartum mental health problems (such as anxiety and depression), affecting more than 20% of mothers, is one of the most common complications around childbirth and gradually have become global public health issues. However, little is known about the course of peripartum mental health problems and possible fluctuations, as well as related risk factors among Chinese women. In addition, there are no effective prediction and preventive strategies for postpartum depression. The Peripartum Mental Health Cohort Study in Guangzhou will collect the epidemiological, clinical information and biological specimens across pregnancy and childbirth to establish trajectory of peripartum mental health and identify the factors influencing the fluctuations and build a comprehensive prediction model of postpartum depression, as well as explore its adverse outcomes. This study would help to determine the timing of screening and target interventions to improve women's and their offspring's health.

Study Type

Observational

Enrollment (Estimated)

3000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

  • Name: Dongmei Wei, MSc
  • Phone Number: 0086 20 38367159

Study Locations

    • Guangdong
      • Guangzhou, Guangdong, China, 510623
        • Recruiting
        • Guangzhou Women And Children's Medical Center
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Probability Sample

Study Population

Pregnant women before 20 weeks of gestation

Description

Inclusion Criteria:

  1. Pregnant women with <20 weeks of gestation
  2. Pregnant women intended to eventually deliver in Guangzhou Women and Children's Medical Center
  3. Permanent residents or families intended to remain in Guangzhou with their child for more than 3 years

Exclusion Criteria:

  1. Combined with heart disease, hypertension, diabetes or hyperthyroidism
  2. Taking anti-depressants and other treatments for depression
  3. Participants was in infection status when the biological samples were collected

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change of prevalence of maternal prenatal depression
Time Frame: before 20th gestational week, after 33th gestational week and prior to delivery
Using Self-rating Depression Scale (SDS) to assess maternal depressive symptoms during pregnancy. SDS scores ≥53 is defined as prenatal depressive symptoms.
before 20th gestational week, after 33th gestational week and prior to delivery
Change of prevalence of maternal postpartum depression in the first year after delivery
Time Frame: 6 weeks, 6 months and 1 year after delivery
Using Edinburgh Postnatal Depression Scale (EPDS) to assess postpartum depressive symptoms. EPDS scores ≥13 is defined as postpartum depressive symptoms.
6 weeks, 6 months and 1 year after delivery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change of prevalence of maternal anxiety during pregnancy
Time Frame: before 20th gestational week, after 33th gestational week and prior to delivery
Using Self-rating Anxiety Scale (SAS) to assess maternal anxiety during pregnancy. SAS scores ≥50 is defined as anxiety.
before 20th gestational week, after 33th gestational week and prior to delivery
Level of maternal cortisol during pregnancy
Time Frame: During period of 2-3 trimesters of pregnancy
Using women's blood samples to test the concentration of cortisol.
During period of 2-3 trimesters of pregnancy
Levels of maternal inflammatory factors during pregnancy
Time Frame: During period of 2-3 trimesters of pregnancy
Using women's blood samples to test the concentration of inflammatory factors, including CRP, IL-6, TNF-α, etc.
During period of 2-3 trimesters of pregnancy
Prevalence of preterm birth, small for gestational age, low birth weight
Time Frame: At delivery
Obtained from electronic medical records.
At delivery
Child's neurodevelopment at early childhood
Time Frame: At child's age of 1 year
Assessed by using the Gesell Developmental Schedules, which includes adaptive, gross motor, fine motor, language, and social function domains. Higher score in each domain is considered a better outcome, while no more than 85 is defined as suspected development delay.
At child's age of 1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Xiu Qiu, PhD, Guangzhou Women And Children's Medical Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 1, 2012

Primary Completion (Estimated)

December 31, 2025

Study Completion (Estimated)

December 31, 2038

Study Registration Dates

First Submitted

July 21, 2020

First Submitted That Met QC Criteria

July 30, 2020

First Posted (Actual)

August 5, 2020

Study Record Updates

Last Update Posted (Actual)

September 13, 2023

Last Update Submitted That Met QC Criteria

September 11, 2023

Last Verified

September 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2018053101

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Depression

3
Subscribe